Cargando…

The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis

Patients with malignant pleural effusion (MPE) who underwent successful pleurodesis survive longer than those for whom it fails. We hypothesize that the therapy-induced inflammatory responses inhibit the cancer progression, and thereby lead to a longer survival. Thirty-three consecutive patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Li-Han, Soong, Thomas C., Chu, Nei-Min, Huang, Chung-Yu, Kao, Shu-Huei, Lin, Yung-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763363/
https://www.ncbi.nlm.nih.gov/pubmed/33322487
http://dx.doi.org/10.3390/jcm9124010
_version_ 1783628000798965760
author Hsu, Li-Han
Soong, Thomas C.
Chu, Nei-Min
Huang, Chung-Yu
Kao, Shu-Huei
Lin, Yung-Feng
author_facet Hsu, Li-Han
Soong, Thomas C.
Chu, Nei-Min
Huang, Chung-Yu
Kao, Shu-Huei
Lin, Yung-Feng
author_sort Hsu, Li-Han
collection PubMed
description Patients with malignant pleural effusion (MPE) who underwent successful pleurodesis survive longer than those for whom it fails. We hypothesize that the therapy-induced inflammatory responses inhibit the cancer progression, and thereby lead to a longer survival. Thirty-three consecutive patients with MPE that were eligible for bleomycin pleurodesis between September 2015 and December 2017 were recruited prospectively. Nineteen patients (57.6%) achieved fully or partially successful pleurodesis, while 14 patients either failed or survived less than 30 days after pleurodesis. Two patients without successful pleurodesis were excluded because of missing data. Interleukin (IL)-1 beta, IL-6, IL-10, transforming growth factor beta, tumor necrosis factor alpha (TNF-α), and vascular endothelial growth factor in the pleural fluid were measured before, and after 3 and 24 h of pleurodesis. Their pleurodesis outcome and survival were monitored and analyzed. Patients who underwent successful pleurodesis had a longer survival rate. Patients without successful pleurodesis had significantly higher TNF-α and IL-10 levels in their pleural fluid than in the successful patients before pleurodesis. Following pleurodesis, there was a significant increment of IL-10 in the first three hours in the successful patients. In contrast, significant increments of TNF-α and IL-10 were found in the unsuccessful patients between 3 and 24 h after pleurodesis. The ability to produce specific cytokines in the pleural space following pleurodesis may be decisive for the patient’s outcome and survival. Serial measurement of cytokines can help allocate the patients to adequate treatment strategies. Further study of the underlying mechanism may shed light on cytokine therapies as novel approaches.
format Online
Article
Text
id pubmed-7763363
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77633632020-12-27 The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis Hsu, Li-Han Soong, Thomas C. Chu, Nei-Min Huang, Chung-Yu Kao, Shu-Huei Lin, Yung-Feng J Clin Med Article Patients with malignant pleural effusion (MPE) who underwent successful pleurodesis survive longer than those for whom it fails. We hypothesize that the therapy-induced inflammatory responses inhibit the cancer progression, and thereby lead to a longer survival. Thirty-three consecutive patients with MPE that were eligible for bleomycin pleurodesis between September 2015 and December 2017 were recruited prospectively. Nineteen patients (57.6%) achieved fully or partially successful pleurodesis, while 14 patients either failed or survived less than 30 days after pleurodesis. Two patients without successful pleurodesis were excluded because of missing data. Interleukin (IL)-1 beta, IL-6, IL-10, transforming growth factor beta, tumor necrosis factor alpha (TNF-α), and vascular endothelial growth factor in the pleural fluid were measured before, and after 3 and 24 h of pleurodesis. Their pleurodesis outcome and survival were monitored and analyzed. Patients who underwent successful pleurodesis had a longer survival rate. Patients without successful pleurodesis had significantly higher TNF-α and IL-10 levels in their pleural fluid than in the successful patients before pleurodesis. Following pleurodesis, there was a significant increment of IL-10 in the first three hours in the successful patients. In contrast, significant increments of TNF-α and IL-10 were found in the unsuccessful patients between 3 and 24 h after pleurodesis. The ability to produce specific cytokines in the pleural space following pleurodesis may be decisive for the patient’s outcome and survival. Serial measurement of cytokines can help allocate the patients to adequate treatment strategies. Further study of the underlying mechanism may shed light on cytokine therapies as novel approaches. MDPI 2020-12-11 /pmc/articles/PMC7763363/ /pubmed/33322487 http://dx.doi.org/10.3390/jcm9124010 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hsu, Li-Han
Soong, Thomas C.
Chu, Nei-Min
Huang, Chung-Yu
Kao, Shu-Huei
Lin, Yung-Feng
The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis
title The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis
title_full The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis
title_fullStr The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis
title_full_unstemmed The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis
title_short The Inflammatory Cytokine Profile of Patients with Malignant Pleural Effusion Treated with Pleurodesis
title_sort inflammatory cytokine profile of patients with malignant pleural effusion treated with pleurodesis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763363/
https://www.ncbi.nlm.nih.gov/pubmed/33322487
http://dx.doi.org/10.3390/jcm9124010
work_keys_str_mv AT hsulihan theinflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT soongthomasc theinflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT chuneimin theinflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT huangchungyu theinflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT kaoshuhuei theinflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT linyungfeng theinflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT hsulihan inflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT soongthomasc inflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT chuneimin inflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT huangchungyu inflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT kaoshuhuei inflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis
AT linyungfeng inflammatorycytokineprofileofpatientswithmalignantpleuraleffusiontreatedwithpleurodesis